Stocks making the biggest moves midday: Costco, Palantir, Gap, Ulta Beauty and more

Midday trading saw significant movement across several sectors: Costco rose over 3% on strong earnings and sales growth, while Ulta Beauty surged nearly 13% after raising its profit forecast. Conversely, Gap plummeted 20% due to a disappointing sales outlook despite a first-quarter earnings beat, and Elastic NV fell 12% on a weaker-than-expected full-year revenue forecast; Regeneron and Sanofi also declined sharply following inconsistent trial results for a respiratory drug.

Analysis

Midday trading showcased significant divergence in corporate performance, heavily influenced by fiscal results and outlooks. Costco shares advanced over 3% on the back of fiscal third-quarter earnings that surpassed analyst expectations and an 8% year-over-year sales increase. Ulta Beauty experienced a substantial rally, surging nearly 13% to a 52-week high, after the company elevated its annual profit forecast and delivered quarterly results that significantly exceeded expectations, driven by reduced inventory losses and successful new product introductions. In the technology sphere, Zscaler climbed 8% following third-quarter results that beat consensus estimates, reporting an adjusted 84 cents per share on $678 million in revenue, compared to forecasts of 76 cents and $666.5 million. Palantir Technologies also saw a gain of over 5%, reportedly linked to news of expanded U.S. government contracts for data compilation. Conversely, Gap shares plummeted 20% as its flat current-quarter sales projection, contrasting with analyst expectations for 0.2% growth, overshadowed its first-quarter earnings and revenue beat. Elastic NV declined 12% after its full-year revenue forecast of $1.655 billion to $1.67 billion fell short of the $1.68 billion anticipated by analysts. Marvell Technology shares fell 6%; its first-quarter adjusted earnings of 62 cents per share, though slightly ahead of the 61 cents expected, did not meet investor enthusiasm. The biopharmaceutical sector witnessed sharp drops for Regeneron Pharmaceuticals and Sanofi, down 18% and 5.6% respectively, following inconsistent late-stage trial data for their co-developed respiratory drug, Itepekimab. PagerDuty shares also decreased by 11% due to a weaker-than-anticipated second-quarter profit forecast, guiding for 19 to 20 cents per share against analyst expectations of 23 cents. This varied performance, reflected in the overall mixed sentiment score of -0.1, underscores the market's acute focus on company-specific fundamentals, particularly future guidance, in shaping investor sentiment.

Key Decisions for Investors

• Investors should heavily weigh forward guidance against historical earnings, as Gap's 20% decline despite a Q1 beat illustrates the market's intolerance for weak outlooks.
• Opportunities may exist in consumer-facing companies like Costco and Ulta Beauty exhibiting strong sales and positive profit revisions, while caution is warranted for those like Gap facing demand headwinds.
• Differentiate within the technology sector, favoring firms like Zscaler that exceed expectations and provide robust forecasts over those like Elastic NV and PagerDuty whose guidance disappoints, and note that even narrow beats like Marvell Technology's may not satisfy current investor expectations.
• Recognize the high-stakes nature of biopharmaceutical investments tied to clinical trial results, exemplified by Regeneron and Sanofi's significant share price drops, and monitor Palantir for both growth potential and risks associated with its expanding government dealings.